company_name,location,website,therapeutic_areas,fit_score,reason_for_fit,num_decision_makers,num_phase2_failed,num_phase3_failed,num_drug_assets
MacroGenics,"Rockville, Maryland, USA",https://www.macrogenics.com,"oncology, autoimmune disorders, infectious diseases",70,"MacroGenics had developed a diabetes drug that was abandoned by Lilly but later revived, indicating a strong scientific rationale despite initial discontinuation. This situation aligns with Convexia's model of identifying assets with potential for rescue and further development.",5,0,0,0
